                         SEQUENCE LISTING

<110>  INSTITUT PASTEUR
       INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
       lnstytut Biochemii i Biofizyki  Polskiej Akademii Nauk
 
<120>  METHODS AND COMPOSITIONS FOR MODIFYING CYSTIC FIBROSIS 
       TRANSMEMBRANE CONDUCTANCE REGULATOR ACTIVITY

<130>  B12425A AD/FY

<140>  PCT/IBXXXX/XXXXXX
<141>  2017-04-28

<150>  US 62/329875
<151>  2016-04-29

<160>  7     

<170>  PatentIn version 3.5

<210>  1
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HK-7 (1-7)

<400>  1

His Leu Leu Gln Phe Asn Lys 
1               5           


<210>  2
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NQ-18 (16-33)

<400>  2

Asn Ala Val Pro Phe Tyr Ala Phe Tyr Gly Cys Tyr Cys Gly Trp Gly 
1               5                   10                  15      


Gly Gln 
        


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NS-9 (105-113)

<400>  3

Asn Gly Tyr Met Phe Tyr Pro Asp Ser 
1               5                   


<210>  4
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NG-13 (105-117)

<400>  4

Asn Gly Tyr Met Phe Tyr Pro Asp Ser Arg Cys Arg Gly 
1               5                   10              


<210>  5
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NR-20 (16-35)

<400>  5

Asn Ala Val Pro Phe Tyr Ala Phe Tyr Gly Cys Tyr Ser Gly Trp Gly 
1               5                   10                  15      


Gly Gln Gly Arg 
            20  


<210>  6
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HK-13 (1-13)

<400>  6

His Leu Leu Gln Phe Asn Lys Met Ile Lys Phe Glu Thr 
1               5                   10              


<210>  7
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CBb unit

<400>  7

His Leu Leu Gln Phe Asn Lys Met Ile Lys Phe Glu Thr Arg Lys Asn 
1               5                   10                  15      


Ala Val Pro Phe Tyr Ala Phe Tyr Gly Cys Tyr Cys Gly Trp Gly Gly 
            20                  25                  30          


Gln Gly Arg Pro Lys Asp Ala Thr Asp Arg Cys Cys Phe Val His Asp 
        35                  40                  45              


Cys Cys Tyr Gly Lys Leu Ala Lys Cys Asn Thr Lys Trp Asp Ile Tyr 
    50                  55                  60                  


Arg Tyr Ser Leu Lys Ser Gly Tyr Ile Thr Cys Gly Lys Gly Thr Trp 
65                  70                  75                  80  


Cys Glu Glu Gln Ile Cys Glu Cys Asp Arg Val Ala Ala Glu Cys Leu 
                85                  90                  95      


Arg Arg Ser Leu Ser Thr Tyr Lys Asn Gly Tyr Met Phe Tyr Pro Asp 
            100                 105                 110         


Ser Arg Cys Arg Gly Pro Ser Glu Thr Cys 
        115                 120         


